Sanofi (NASDAQ:SNY) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 17.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 21,128 shares of the company’s stock after buying an additional 3,082 shares during the quarter. Blue Trust Inc.’s holdings in Sanofi were worth $1,019,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the third quarter valued at approximately $29,000. Concord Wealth Partners boosted its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the period. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $54,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Sanofi stock opened at $52.97 on Wednesday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a 50 day simple moving average of $48.90 and a 200-day simple moving average of $52.22. The stock has a market capitalization of $134.43 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.